Sanofi celebrates 50th anniversary of France – China relations
27 January 2014 | By Sanofi
Sanofi announced its participation in the commemoration of the 50th anniversary of diplomatic relations between France and the People's Republic of China...
List view / Grid view
News
Pfizer announces top-line results from two Phase 3 trials of Dacomitinib on patients with refractory advanced non-small cell lung cancer
27 January 2014 | By Pfizer
An Ongoing, Third Phase 3 Trial is Evaluating Dacomitinib in First-Line in EGFR-Mutant NSCLC...
Novartis recognized among world’s most sustainable companies in Corporate Knights Global 100
27 January 2014 | By Novartis
Novartis is pleased to announce that it has been named among the 2014 Corporate Knights Global 100...
Novartis to request re-examination of serelaxin (RLX030) in acute heart failure (AHF) for conditional marketing authorization in EU
24 January 2014 | By Novartis
Novartis announced it will shortly submit a revised filing package, including new data analyses, for re-examination for conditional approval of RLX030 (serelaxin) for acute heart failure...
Novartis reports positive opinion from CHMP for Xolair® in severe form of skin disease CSU, a debilitating form of hives and chronic itch
Novartis announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion for the use of Xolair®...
Update on Regarding the Import Alert on Ranbaxy’s Toansa Plant
24 January 2014 | By Daiichi Sankyo Company
Ranbaxy Laboratories Limited announced that the US FDA notified the company that it is prohibited from manufacturing and distributing active pharmaceutical ingredients from its facility in Toansa, India, for FDA-regulated drug products...
Regarding the import alert on Ranbaxy’s Toansa Plant
24 January 2014 | By Daiichi Sankyo
Daiichi Sankyo Company Ltd. announced that the US Food and Drug Administration has issued an import alert on January 23 on Active Pharmaceutical Ingredients...
Amgen announces positive top-line results from Phase 3 GAUSS-2 trial of Evolocumab (AMG 145) in statin intolerant patients with high cholesterol
23 January 2014 | By Amgen
Study meets co-primary endpoints of LDL cholesterol reduction...
Pfizer reports top-line results from ALO-02 Phase 3 study
23 January 2014 | By Pfizer Inc
Pfizer Inc. announced top-line results from a Phase 3 study of investigational agent ALO-02 in patients with moderate-to-severe chronic low back pain...
Janssen announces new group targeting unmet global health needs
22 January 2014 | By Johnson & Johnson
Janssen global public health to oversee R&D and access strategy development for growing portfolio of transformational medicines...
XIGDUO™ (dapagliflozin and metformin hydrochloride) approved in the European Union for type 2 diabetes
22 January 2014 | By AstraZeneca
AstraZeneca and Bristol-Myers Squibb announced that Xigduo™ has been granted Marketing Authorisation by the European Commission for the treatment of type 2 diabetes in the European Union...
Syrris Atlas has the Midas touch with nanoparticles
21 January 2014 | By kdm communications limited
Spanish biotechnology company Midatech Biogune is taking advantage of Syrris Atlas Potassium reactor systems to produce custom-made functionalized gold nanoparticles for medicinal use...
Roche provides update on the first two of six phase III studies of bitopertin in schizophrenia
21 January 2014 | By Roche
Roche announced that two phase III studies of its investigational medicine bitopertin (RG1678) in adults with persistent, predominant negative symptoms of schizophrenia failed to meet their primary endpoints...
New global alliance to develop class-leading technology
21 January 2014 | By BMG Labtech
A team of world leaders in the growing scientific field of biomolecular interaction, relating to basic biomedical research and the discovery of new pharmaceuticals, has been the recipient of a new Australian Research Council Linkage Grant...
Novo Nordisk launches its shortest needle: NovoFine® Plus, compatible with all major pen devices
20 January 2014 | By Novo Nordisk
Canada is the first country to make NovoFine® Plus available and will be followed by several other countries during 2014 and 2015...
